Does pre-existing cognitive impairment no-dementia influence the outcome of patients treated by intravenous thrombolysis for cerebral ischaemia?
rt-PA is also beneficial after 80 years of age. Cognitive impairment being frequent in elderly subjects, more patients eligible for rt-PA will have prestroke cognitive impairment. They often have an underlying brain pathology associated with an increased bleeding risk: brain microbleeds and leukoaraiosis are frequent and usually associated with cerebral amyloid angiopathy in Alzheimer's disease or hypertensive microangiopathy in vascular dementia. They are also less likely to recover because of pre-existing brain lesions, impaired brain plasticity and possibly higher sensitivity to the neurotoxic effects of rt-PA. Three studies evaluated the influence of pre-existing dementia on outcome after thrombolysis.
2-4 They provided conflicting results, that is, a tendency towards increased in-hospital mortality and symptomatic haemorrhagic transformation (sHT), 3 increased in-hospital mortality without increase in sHT 4 and no significant difference in outcome. 5 However, they did not take into account important predictors of outcome such as baseline stroke severity and did not evaluate the proportion of independent survivors at 3 months. Moreover, they did not take into account CIND.
Therefore, the question of whether rt-PA is safe and effective in ischaemic stroke patients with cognitive impairment remains unsettled. We evaluated this question as an ancillary analysis of data available in two previous studies from our group. The aim of our study was to evaluate whether patients with CIND who received i.v. rt-PA differ in outcome compared with cognitively normal subjects.
METHODS
This study was conducted in patients treated by i.v. rt-PA for cerebral ischaemia in the stroke unit of the Lille University hospital who participated in two ongoing studies of biomarkers, that is, Biostroke and Strokdem. Patients already known as demented before stroke and patients with a prestroke modified Rankin scale (mRS)≥2 were not eligible.
Stroke severity was assessed by the National Institutes of Health Stroke Scale (NIHSS) before the bolus. The systematic assessment of the pre-existing cognitive status was conducted within 48 h of stroke onset with a French translation of the short version of the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE), a score of 3 or less meaning normal cognition, a score of 3.44 or more meaning pre-existing dementia and a score higher than 3 but lower than 3.44 meaning CIND. 4 Patients diagnosed as demented by the IQCODE were also excluded.
We defined sHT according to the European cooperative acute stroke study-2 definition, and the presumed cause of ischaemic stroke according to the Trial of Org 10172 in Acute Stroke Treatment criteria. Outcomes at 3 months were assessed by the mRS.
The primary endpoint was the proportion of patients with favourable outcome (mRS 0-1) at 3 months. Secondary endpoints were the proportion of sHT at 7 days, relative improvement in NIHSS scores between baseline and 7 days in survivors (defined as Δ=[baseline NIHSS-NIHSS at 7 days]/baseline NIHSS), the proportion of independent survivors (mRS 0-2) at 3 months and the whole spectrum of the mRS at 3 months. The study was approved by the ethical committee of Lille (CCPPRB), and all patients or their relatives signed a written informed consent for participation and follow-up.
We performed the statistical analysis with the SPSS V.15.0 package for windows and CI analysis software. We determined median values, IQRs and percentages (%). We compared groups for categorical variables, with the χ 2 test with Yates' correction or Fisher exact test when appropriate, or unadjusted ORs with 95% CI. For continuous variables, we used the MannWhitney U test. Predictors of good outcome (mRS 0-1 at 3 months) were defined by a logistic regression analysis.
RESULTS
Of 510 consecutive patients treated by i.v. rt-PA, 99 (19.4%) met inclusion criteria: they did not significantly differ from the other 411 patients for most baseline characteristics, but they were younger (median 67 years vs 72 years; p=0.048) and were less likely to have arterial hypertension (OR: 0.63; 95%CI 0.40 to 0.98). Of these 99 patients, 68 (68.7%) had a normal cognition, and 31 (31.3%) met criteria for CIND.
CIND patients were older, but did not differ from cognitively normal patients for other demographic or baseline characteristics. They did not differ for the rate of sHT at 7 days and mRS at 3 months ( p=0.724). Details are provided in table 1. Baseline NIHSS was the only independent predictor of mRS 0-1 at 3 months (adjusted OR: 0.835 for 1 point increase, 95% CI 0.765 to 0.911; p<0.001), but age, CIND and onset to needle time were not ( p=0.438, 0.882, 0.893, respectively).
DISCUSSION
Our study has shown that the outcome of patients with CIND who are treated with rt-PA did not significantly differ from that of cognitively normal patients.
To our knowledge this is the only study that has systematically evaluated the preexisting cognitive state in patients treated by i.v. rt-PA. The absence of difference in the rates of sHT and mortality suggests an overall good safety profile.
The main limitations of our study are the small sample size and the small number of patients with CIND. This is due to the protocol that excluded patients with baseline mRS≥2. The information provided by this preliminary study is that there is currently no reason to exclude a patient from i.v. thrombolysis because of CIND. However, caution is needed because of the lack of reliable information in the literature, the small sample size of our study, the small number of events with a lack of statistical power and the poor external validity of the study, only 19% of patients having been included.
